ArticleTranslational lung cancer research2026
Neoadjuvant immunochemotherapy in potentially resectable small cell lung cancer: a real-world retrospective analysis.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and validation of a nomogram for predicting overall survival in small cell lung cancer: a multicenter analysis integrating multimodal therapy and molecular pathology.Translational lung cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Small cell lung cancer (SCLC) is an aggressive malignancy with limited treatment options. Recent advancements in immunotherapy have shown promise in improving patient outcomes. However, the role of neoadjuvant immunotherapy in potentially resectable SCLC remains unclear. This study aimed to explore the feasibility of neoadjuvant therapy in this population and assess whether the addition of immunotherapy to neoadjuvant therapy further improves the prognosis of limited-stage SCLC (LS-SCLC) patients. Methods: We retrospectively analyzed the medical records of 59 patients with stage IIB-III SCLC who received neoadjuvant therapy followed by surgery at West China Hospital between 2018 and 2024. The patients were divided into two groups: Group A, which included patients who received chemotherapy alone, and Group B, which included patients who received chemotherapy combined with immunotherapy. We evaluated the pathological complete response (pCR) rate, disease-free survival (DFS), and safety profiles of both treatment regimens. Results: The pCR rate was significantly higher in Group B than Group A (46.9% Conclusions: Our findings suggest that neoadjuvant immunotherapy combined with chemotherapy followed by surgery may provide a survival benefit over chemotherapy alone in the treatment of resectable SCLC. The combined treatment approach significantly improved the pCR rates and DFS of the patients with resectable SCLC. While our study highlights the potential of this approach, further prospective multi-center studies need to be conducted to validate these findings and explore biomarkers for personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.